AU2003227862B2 - An EPHRIN-B receptor protein involved in carcinoma - Google Patents

An EPHRIN-B receptor protein involved in carcinoma Download PDF

Info

Publication number
AU2003227862B2
AU2003227862B2 AU2003227862A AU2003227862A AU2003227862B2 AU 2003227862 B2 AU2003227862 B2 AU 2003227862B2 AU 2003227862 A AU2003227862 A AU 2003227862A AU 2003227862 A AU2003227862 A AU 2003227862A AU 2003227862 B2 AU2003227862 B2 AU 2003227862B2
Authority
AU
Australia
Prior art keywords
polypeptide
ccmp
antibody
expression
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003227862A
Other languages
English (en)
Other versions
AU2003227862A1 (en
Inventor
Robert Simon Boyd
Graham Charles Fletcher
Lyndsey J. Hudson
Sonal Patel
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of AU2003227862A1 publication Critical patent/AU2003227862A1/en
Application granted granted Critical
Publication of AU2003227862B2 publication Critical patent/AU2003227862B2/en
Assigned to UCB PHARMA S.A. reassignment UCB PHARMA S.A. Request for Assignment Assignors: OXFORD GLYCOSCIENCES (UK) LTD
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003227862A 2002-04-09 2003-04-09 An EPHRIN-B receptor protein involved in carcinoma Ceased AU2003227862B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0208089.3A GB0208089D0 (en) 2002-04-09 2002-04-09 Protein
GB0208089.3 2002-04-09
PCT/GB2003/001593 WO2003087841A2 (en) 2002-04-09 2003-04-09 An ephrin-b receptor protein involved in carcinoma

Publications (2)

Publication Number Publication Date
AU2003227862A1 AU2003227862A1 (en) 2003-10-27
AU2003227862B2 true AU2003227862B2 (en) 2008-08-28

Family

ID=9934469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227862A Ceased AU2003227862B2 (en) 2002-04-09 2003-04-09 An EPHRIN-B receptor protein involved in carcinoma

Country Status (7)

Country Link
US (2) US7655426B2 (https=)
EP (1) EP1497659A2 (https=)
JP (2) JP2005522229A (https=)
AU (1) AU2003227862B2 (https=)
CA (1) CA2479835C (https=)
GB (1) GB0208089D0 (https=)
WO (1) WO2003087841A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610685A1 (en) 2005-06-03 2006-12-14 Novartis Vaccines And Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
EP2057193B1 (en) * 2006-08-04 2013-12-18 Novartis AG Ephb3-specific antibody and uses thereof
KR101519672B1 (ko) * 2006-12-07 2015-05-29 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen
WO2002021996A2 (en) * 2000-09-15 2002-03-21 Eos Biotechnology, Inc. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506205A (en) * 1993-11-24 1996-04-09 Ono Pharmaceutical Co., Ltd. Polypeptide of protein p140 and DNAs encoding it
US5457048A (en) 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
EP0756627A1 (en) 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU5621501A (en) 2000-03-27 2001-10-08 Bayer Aktiengesellschaft Regulation of human ephrin-like receptor
AUPQ909100A0 (en) 2000-07-28 2000-08-24 Ludwig Institute For Cancer Research A method for diagnosis and treatment
AU2002314433A1 (en) 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen
WO2002021996A2 (en) * 2000-09-15 2002-03-21 Eos Biotechnology, Inc. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators

Also Published As

Publication number Publication date
AU2003227862A1 (en) 2003-10-27
EP1497659A2 (en) 2005-01-19
JP2010101901A (ja) 2010-05-06
US7655426B2 (en) 2010-02-02
CA2479835A1 (en) 2003-10-23
CA2479835C (en) 2013-10-01
WO2003087841A2 (en) 2003-10-23
WO2003087841A3 (en) 2004-02-26
US20050260209A1 (en) 2005-11-24
US20110150877A1 (en) 2011-06-23
JP2005522229A (ja) 2005-07-28
GB0208089D0 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
AU2002343109A1 (en) Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers
US20110150877A1 (en) Ephrin-b receptor protein involved in carcinoma
AU2004285339B2 (en) A protein involved in ovarian cancer
AU2003249072B2 (en) PTK7 protein involvement in carcinoma
US20060088537A1 (en) Protein involved in cancer
EP1257827A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
US20090258019A1 (en) Diagnosis of carcinoma using RAIG1 polypeptides
US7297760B2 (en) Cancer associated protein
US20040166517A1 (en) Cancer associated protein
US20070141061A1 (en) Protein involved in carcinoma
WO2003074557A1 (en) Novel b-cell malignancy-associated protein

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UCB PHARMA S.A.

Free format text: FORMER OWNER WAS: OXFORD GLYCOSCIENCES (UK) LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired